Oversættelse af europæisk patentskrift

Patent- og Varemærkestyrelsen


Oversættelsen bekendtgjort den: 2016-11-28

Dato for Den Europæiske Patentmyndigheds bekendtgørelse om meddelelse af patentet: 2016-08-24

Europæisk ansøgning nr.: 04811413.6

Europæisk indleveringsdag: 2004-11-19

Den europæiske ansøgnings publiceringsdag: 2006-08-02

International ansøgning nr.: US2004038697

International publikationsnr.: WO2005051403

Prioritet: 2003-11-21 US 719569

Designerede stater: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LU MC NL PL PT RO SE SI SK TR

Patenthaver: Hill’s Pet Nutrition, Inc., 400 Southwest 8th Street, Topeka, KS 66603, USA

Oplysninger: KHO0, Christina, 1100 Andover Street, Lawrence, KS 66049, USA GROSS, Kathy Lynn, 3627 NW 94th Street, Topeka, KS 66618-9500, USA GIBSON, Glenn, 32 Oatlands Road, Shinfield Reading RG2 9DW, Storbritannien

Fuldmægtig i Danmark: Zacco Denmark A/S, Arne Jacobsens Allé 15, 2300 København S, Danmark

Benævnelse: Sammensætning til behandling af inflammation i mævetarmkanalen hos kæledyr

Fremdragne publikationer:
WO-A1-00/54788
WO-A1-98/26787
WO-A2-00/53030
FR-A1- 2 815 823
US-A- 5 444 054
US-A- 6 087 092
US-B1- 6 197 361
US-B1- 6 203 797


Fortsættedes ...
2003 (2003-01-01), page 508, XP009127856 ISSN: 1060-2011
DESCRIPTION

Background of the Invention

[0001] Maintaining the well being of the GI tract of a mammal is a very desirable goal. Particularly relevant are inflammatory conditions of the GI tract. The Desulfovibrio spp. bacteria (including but not limited to desulfovibrio, intestinale, vulgaris, etc.) are sulfate reducing bacteria that produce hydrogen sulfide which when released by the bacteria, can cause inflammation cells of the GI tract. Helicobacter bacteria (including but not limited to helommi, felix, pylori, bizzozorno, salmonis) can cause ulcers and inflammation of the cells of the stomach and upper intestines. Some signs of inflammation of the GI tract include acute or chronic diarrhea, soft stools, blood in stool, vomiting, poor nutrient digestion and absorption, weight loss and poor appetite. Diseases such as gastritis, enteritis, inflammatory bowel disease, ulcers, some types of cancer and others are known to have GI inflammation as a main component. Pathogenic bacteria such as Desulfovibrio spp., which reduce sulfate to sulfide, can also cause an increase in gas or stool odor due to increased levels of sulfide or other odiferous compounds in the stool.

[0002] We have now found that cats with inflammatory bowel disease (IBD) have a higher number of Desulfovibrio and/or Helicobacter spp. than normal, healthy cats. We have also found that Helicobacter was detectable in all cats with inflammatory bowel disease (IBD) whereas only 5/12 normal cats treated had detectable levels of helicobacter. We have also found that 45% of tested IBD cats had levels of bifidobacteria, a beneficial bacterial group, below standard detection levels, while 9% of normal, healthy cats had bifidobacteria below standard detection levels.

Summary of the Invention

[0003] In accordance with the invention, there is an orally edible food composition for use by a companion animal comprising an edible food composition in combination with a component which reduces the levels of Desulfovibrio and/or Helicobacter spp. in the companion animal, as defined in the appended claims.

[0004] Also disclosed is a method for reducing the level of Desulfovibrio and/or Helicobacter spp. in a companion pet which comprises orally administering the food of the invention.

Detailed Description of the Invention

[0005] As stated previously, it has now been discovered that Desulfovibrio spp. are higher in cats with a GI tract inflammation disorder, IBD, than normal cats not having this disorder. Therefore, it would be beneficial to any companion pet having a higher level of Desulfovibrio and/or Helicobacter spp. with or without overt clinical signs of a disease or disorder generally accompanied by GI tract inflammation to have their levels reduced. Benefits can also be derived from preventing Desulfovibrio and/or Helicobacter spp. from rising, that is a preventive effect.

[0006] The bacteria can be reduced by active agents. These include antibacterial materials such as antibiotics, chemotherapeutics and the like. Surprisingly, fibers can also reduce levels of Desulfovibrio and/or Helicobacter spp. as well. Examples of such fibers include an oligosaccharide, a galactan, a beta glucan and mixtures thereof. Examples of oligosaccharides include xylooligosaccharide, galactooligosaccharide, fructooligosaccharide. Examples of a beta glucan include yeast cell extract, sprouted barley, oat fiber, curdlan (polysaccharide from microbial fermentation). Examples of galactans include arabinoxygallactan.

Preferably a polyphenol(s) can also be present with the active agent, particularly where the active agent is a fiber, and more particularly where the fiber is a galactan such as arabinoxylactan. The polyphenol is generally of a structure having at least two phenols and more preferably is a flavonoid such as a taxifolin. Minimum quantities of the polyphenol in the composition are a minimum of about 0.01, 0.05 or 0.1 wt% as measured on a companion pet's daily diet. The maximum generally does not exceed about 2, 1, or 0.75 wt% as measured on a companion pet's daily diet, all weights dry matter basis.

[0007] An anti Desulfovibrio and/or Helicobacter spp. effective amount of component can be employed. An antibacterial agent such as an antibiotic or chemotherapeutic agent can be provided orally to the pet at a minimum of about 2 & 5 mg/kg of body weight. Maximums are generally no more than about 25, 50 mg/kg of body weight. With respect to a fiber, the minimum is about 0.1, 0.5, or 1.0 wt % and the maximum generally should not exceed about 5, 10, or 20 wt % as measured on a companion pet's daily diet, dry matter basis.
**Desulfovibrio** and/or **Helicobacter spp.** reduction can be effective in helping to manage diseases and conditions in a companion pet wherein GI tract inflammation is a main component. Examples of companions pets are dogs, cats, horses.

**Example - Showing presence of increased level of pathogenic bacteria in IBD cats.**

1. **Protocol for screening of fecal samples from cats:**

   Fecal samples were collected from normal healthy cats and those cats diagnosed with IBD. The normal cats were maintained on **Science Diet** Feline maintenance® dry while the cats with IBD were maintained on a therapeutic gastrointestinal diet. The fecal samples were frozen at -70°C prior to analysis. For analysis, samples were mixed with phosphate buffer saline to a ratio of 1:10 (w/w), vortexed with glass beads and centrifuged to remove particulate matter. An aliquot of 375 μl sample was added to a tube containing 1.125ml of 4% paraformaldehyde and left at 4°C for 4-5 hours. The samples were centrifuged and washed twice in PBS, then mixed with 150 μl of filtered ethanol and stored at -20°C prior to fluorescent in situ hybridization analysis (FISH for microbial enumeration). Genus specific 16S RNA-targeted probes were synthesized and monolabelled at the 5’ end with fluorescent dye to detect the bacteria of interest in the fermentation media. Total nucleic acid was stained to obtain the total cell counts. The data are expressed as log_{10} cells/g feces. FISH allows bacterial quantification of stored samples and includes both culturable and non-culturable diversity.

**Results**

<table>
<thead>
<tr>
<th></th>
<th>Normal</th>
<th>IBD</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Desulfovibrio</strong> feces</td>
<td>cfu/g  7.0 ± 2.5</td>
<td>7.7 ± 0.6</td>
</tr>
<tr>
<td><strong>Helicobacter</strong> feces</td>
<td>cfu/g  2.9 ± 3.6</td>
<td>7.3 ± 0.6</td>
</tr>
</tbody>
</table>

These results show that cats with GI tract inflammation, specifically IBD, had an increased quantity of pathogenic bacteria present in the GI tract.

**Example 2 Invivo Effect of AG on desulfovibrio in IBD and normal cats**

2. **Protocol for feeding study**

Eleven (11) cats with IBD and 10 normal healthy cats were fed foods containing 1.0% beetpulp with 0.6% arabinogalactan extract from the Western larch tree. The extract was approximately 90 wt % arabinogalactan and about 4 wt % polyphenols, the predominant polyphenol being taxifolin, the remainder being moisture, all on a dry matter basis for two weeks. Following this, the cats were switched to food containing 1.5 % beetpulp alone. Fecal samples were collected on days 0, day 14 and day 28. The samples were prepared as follows for FISH analysis: To freeze each fecal sample, 5 g of feces was suspended in anaerobic phosphate buffered saline (PBS) at pH 7.3 in a sterile bag or plastic container to give a final concentration of 10% (45 ml for 5 g). The slurry was homogenized/mixed in the bag to avoid contamination. A different container was used for each sample. 5 ml of the slurry was mixed with an equal amount of glycerol to give a 50:50 mix which was frozen for analysis by FISH.

**Results:**

Thirteen (13) complete sets of fecal samples were obtained. When the cats were on food containing 0.6% AG extract, 4/13 cats had decreased *Desulfovibrio* spp. of 0.3 log units and above. 8/13 cats had small decreases or no change in the levels.
of Desulfovibrio spp. while only 1/13 cats had an increase in Desulfovibrio spp. When the cats were switched to food without AG, 10/13 cats had increased levels of Desulfovibrio spp. of 0.3 log units and above, 2/13 cats had no change and only 1/13 cats had decreased levels of Desulfovibrio spp.

[0014] The results show that AG extract was able to prevent an increase in Desulfovibrio spp. in most of the cats and tended to decrease in some of the cats. This was at the level that was fed compared to beet pulp, which tended to cause an increase in Desulfovibrio spp. in most of the cats.

Example 3 - In vitro experiment showing that various fibers decreased levels of Desulfovibrio spp.

Fermentation vessels containing anaerobic phosphate buffered medium were prepared and 1 ml canine fecal inoculum (10% w/v fecal sample to buffer) added. The composition of the media was as described in Sunvold GD, Hussein HS, Fahey GC, Merchen NR, and Reinhart GA (1995). In vitro fermentation of selected fiber sources by dogs fecal inoculum and in vivo digestion and metabolism of fiber supplemental diets. J. Animal Sci. 73:1099-1109 (1995). Fermentations were carried out at 39° C. Experiments were conducted in a blind-coded manner with different fibers. After 8 hours incubation, 1 ml culture fluid was removed. An aliquot of this was prepared for FISH. After 8 hours, 1 ml of culture fluid was removed and mixed with 4% paraformaldehyde in PBS and fixed for FISH. Genus specific 16S rRNA-targeted probes were synthesized and monolabeled at the 5’ end with fluorescent dye to detect bacteria of interest in the fermentation media. Total nucleic acid was stained to obtain total microbial counts. The results showed that several different types of fibers were able to decrease the growth of Desulfovibrio spp. by 0.5 to 1.0 log units during the 8 hour fermentation (see Table 2).

Table 2

<table>
<thead>
<tr>
<th>Numbers of Desulfovibrio spp. after 8 hour incubation (log cfu/ml of fecal inoculum).</th>
</tr>
</thead>
<tbody>
<tr>
<td>Log_{10} CFU AT 0 HOUR              LOG_{10} CFU AT 8 HOUR</td>
</tr>
<tr>
<td>Arabinogalactan   7.5 ± 0.3                         6.4 ± 1.0</td>
</tr>
<tr>
<td>Xylooligosaccharide 7.2 ± 0.4                      6.8 ± 0.9</td>
</tr>
<tr>
<td>Galacto-oligosaccharide 7.0 ± 1.0                   6.8 ± 0.9</td>
</tr>
<tr>
<td>Fructooligosaccharide 6.9 ± 1.0                     6.3 ± 0.8</td>
</tr>
<tr>
<td>Inulin            7.3 ± 0.2                         6.4 ± 1.0</td>
</tr>
<tr>
<td>Sprouted barley   6.8 ± 0.9                         5.8 ± 0.0</td>
</tr>
</tbody>
</table>

SUMMARY

[0016] Therefore, we have shown both in vitro and in vivo that AG decreased the level of Desulfovibrio spp.

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader’s convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Non-patent literature cited in the description

* J. Animal Sci., 1995, vol. 73, 1099-1109 [0015]
**Patentkrav**

1. Fiber til anvendelse ved behandling af inflammation i mavetarmkanalen (GI) hos et kæledyr, hvor inflammationsbehandlingen omfatter at indgive en sammensætning omfattende fiber oralt til kæledyret, hvor inflammationsbehandlingen omfatter at reducere mængden af *Desulfovibrio*- og/eller *Helicobacter*-arten i mavetarmkanalen, og hvor fiberen er udvalgt fra gruppen bestående af en oligosaccharid, en galactan, en betaglucan og en blanding deraf.

2. Fiber til anvendelse ifølge krav 1, hvor kæledyret har behov for indgivelsen.

3. Fiber til anvendelse ifølge krav 2, hvor kæledyret er en hund eller kat.

4. Fiber til anvendelse ifølge et af kravene 1 til 3, hvor fiberen er udvalgt fra gruppen bestående af arabinogalactan, xylooligosaccharid, galactooligosaccharid, fructooligosaccharid, inulin, spiret byg og en blanding deraf.

5. Fiber til anvendelse ifølge et hvilket som helst foregående krav, hvor sammensætningen omfatter fiber i en mængde på 0,1%, 0,5%, 1%, 5%, 10% eller 20% på tørstofbasis.

6. Fiber til anvendelse ifølge et hvilket som helst foregående krav, hvor sammensætningen yderligere omfatter en polyphenol.

7. Fiber til anvendelse ifølge et hvilket som helst foregående krav, yderligere omfattende at reducere lugt fra tarmluft og/eller lugt fra afføring.